Forum Financial Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Forum Financial Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,546	Closed	-$615K	–	364
2025 Q4	$615K	Sell	1,546 -10	-0.6%	-$4.43K	0.01%	394
2025 Q3	$710K	Hold	1,556	–	–	0.01%	325
2025 Q2	$507K	Buy	1,556 +129	+9%	+$35.7K	0.01%	401
2025 Q1	$385K	Sell	1,427 -37	-3%	-$9.51K	0.01%	466
2024 Q4	$344K	Buy	1,464 +5	+0.3%	+$1.31K	0.01%	534
2024 Q3	$401K	Buy	1,459 +2	+0.1%	+$521	0.01%	398
2024 Q2	$354K	Hold	1,457	–	–	0.01%	417
2024 Q1	$218K	Hold	1,457	–	–	﹤0.01%	660
2023 Q4	$279K	Buy	+1,457	New	+$248K	0.01%	481
2023 Q1	–	Sell	-982	Closed	-$233K	–	621
2022 Q4	$233K	Buy	+982	New	+$209K	0.01%	487

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Forum Financial Management's ALNY Position: Q1 2026 in Review

Forum Financial Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,546 shares — an estimated $615K sold.

Forum Financial Management first reported a position in ALNY in Q4 2022 and held it in 10 quarters. The position peaked at $710K in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Forum Financial Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Forum Financial Management sold 1,546 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $615K.
Forum Financial Management first reported a position in Alnylam Pharmaceuticals in Q4 2022 and held it in 10 quarters.
Forum Financial Management's Alnylam Pharmaceuticals position peaked at $710K in Q3 2025.
791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Forum Financial Management's 13F filing for Q1 2026, filed 23 Apr 2026.